Is Gland Pharma overvalued or undervalued?

As of 3 November 2025, Gland Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently considered overvalued. Key ratios include a PE ratio of 42.12, an EV to EBITDA of 22.01, and a PEG ratio of 6.32, all of which are considerably higher than industry norms.
In comparison to its peers, Gland Pharma's valuation metrics stand out, with Sun Pharma having a PE of 35.62 and Divi's Lab at a staggering PE of 78.12. Other competitors like Cipla and Dr. Reddy's Labs show more attractive valuations with PE ratios of 22.44 and 17.3, respectively. Despite Gland Pharma's recent stock performance showing a 19.57% return over the past year compared to the Sensex's 5.34%, the elevated valuation suggests that the stock may not be a prudent investment at this time.